Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 20,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $44.98, for a total value of $899,600.00. Following the transaction, the vice president now directly owns 32,500 shares of the company’s stock, valued at approximately $1,461,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $43.55 on Friday. The firm has a market capitalization of $2,230.00, a PE ratio of 39.59 and a beta of 1.17. Supernus Pharmaceuticals Inc has a twelve month low of $23.10 and a twelve month high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% on a year-over-year basis. equities analysts forecast that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.
Several research analysts have commented on SUPN shares. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. FBR & Co started coverage on Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price for the company. Janney Montgomery Scott raised Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Monday, December 4th. Stifel Nicolaus raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, November 7th. Finally, Cowen set a $50.00 target price on Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $49.90.
ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3145265/insider-selling-supernus-pharmaceuticals-inc-supn-vp-sells-20000-shares-of-stock.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.